Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

ArmaGen Technologies Inc (AKA: Neurogene Technologies LLC)
Profile last edited on: 2/16/2022      CAGE: 443R2      UEI: TUSJK4JGAPK9

Business Identifier: Recombinant fusion proteins targeting blood-brain barrier (BBB) for brain and spinal cord diseases
Year Founded
2001
First Award
2002
Latest Award
2016
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

914 Colorado Boulevard
Santa Monica, CA 90401
   (310) 917-1275
   contact@armagen.com
   www.armagentech.com
Location: Single
Congr. District: 33
County: Los Angeles

Public Profile

Formerly known as Neurogene Technologies LLC, ArmaGen Technologies, Inc. is a biotechnology company developing therapies for severe neurological disorders. The company is advancing innovative therapies for the treatment of currently unaddressed neurological complications of lysosomal storage disorders (LSDs), as well as neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Most medications are unable to penetrate the blood-brain barrier (BBB) - creating a largely unmet medical need to treat neurological complications of many diseases, including LSDs and neurodegenerative diseases. ArmaGen’s pipeline is based on decades of work developing engineering therapies non-invasively to penetrate the BBB - a unique and dominant IP portfolio. Currently, ArmaGen has eight compounds in development: a lead product candidates are AGT-182 for Hunter syndrome, which is in Phase 1 clinical trials, and AGT-181 for Hurler syndrome, which is in Phase 2 trials.

Extent of SBIR involvement

User Avatar
Phase I Awards
17
Phase II Awards
13
Conversion Rate
76.47%
Phase I Dollars
$2,180,384
Phase II Dollars
$17,291,607
Total Awarded
$19,471,991

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
15-19

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2016 2 NIH $1,185,571
Project Title: Sulfamidase Brain Drug Delivery in Sanfilippo Syndrome
2014 2 NIH $1,129,664
Project Title: Manufacturing of Trojan Horse-Tnfr Decoy Receptor Fusion Protein
2014 2 NIH $1,156,200
Project Title: Metachromatic Leukodystrophy Enzyme Drug Development
2013 2 NIH $1,163,649
Project Title: Enzyme Replacement Therapy of the Brain in Mucopolysaccharidosis Type Ii
2012 2 NIH $991,996
Project Title: Bioengineering Of A New Antibody Drug Delivery Technology

Key People / Management

  Mathias Schmidt -- Chief Executive Officer

  Sheri Barrack -- Senior Vice President of Pharma Development

  Ruben J Boado

  James Callaway -- Chief Executive Officer and Member of the Board of Directors

  Ka-Wai Hui

  Derek Kelaita -- Vice President, Business Development

  Zhiqiang Lu

  William Pardridge -- Founder and Chief Scientific Officer

  Patrice Rioux -- Senior Vice President of Global Clinical Development

  Yufeng Zhang

  Yun Zhang

Company News

Jul 14 2016
ArmaGen Presents Data from First Cohort of Phase 1/2a of AGT-182 for Treatment of Hunter Syndrome
Mar 31 2016
ArmaGen Announces Initiation of Phase 2 Proof-of-Concept Clinical Trial in Brazil to Study AGT-181 for the Treatment of Hurler Syndrome
Jul 23 2014
ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome
Jul 18 2013
ARMAGEN® RECEIVES US ORPHAN DESIGNATION FOR LEAD PRODUCT AGT-182
Apr 14 2013
ArmaGen announces $17M Series A financing